Dublin, May 20, 2021 (GLOBE NEWSWIRE) — The “Global Gamma Delta T Cell Cancer Therapy Opportunity and Clinical Trials Insight 2026” report has been added to ResearchAndMarkets.com’s to offer.
In recent years, the idea of immunotherapy of the ability to manipulate immune cells into targeting tumor cells is gaining traction in the field of cancer therapies. Since then, scientists have developed a wide variety of potential candidates that have shown encouraging results in cancer treatment.
The recent clinical success of chimeric antigen receptor in the treatment of hematologic malignancies has clearly led to the explosion in the field of adoptive cell therapy for cancer. Researchers are currently working to translate this exciting technology into solid tumors and develop allogeneic turn-key therapies.
Advances in biotechnology have allowed researchers to identify gamma-delta T cells that play a potential role in cancer immunosurveillance and have the potential to overcome the challenges of adoptive cell therapy. The cells have both innate and adaptive properties, making them a bridge between adaptive and innate immunity. In addition, these subsets of cells produce various cytokines, chemokines and growth factors that help generate an immune response against the tumor cells.
Since their identification, gamma-delta T cells have been attractive candidates for adoptive T cell therapy due to their unique biology and beneficial properties in cancer treatment. The unique ability to independently target cells to an important histocompatibility complex and recognize a wider range of antigens has attracted a lot of interest from the researchers. There are currently no approved gamma-delta T therapies, but there is a pool in clinical trials. The majority of candidates belong to an early stage clinical trial, which takes approximately 5-7 years to reach the market.
The encouraging response of gamma-delta T-cell therapy in cancer treatment has prompted researchers to exploit the role of gamma-delta T-cells in other diseases as well. Researchers have initiated a number of preclinical studies to identify their role in diabetes, infectious and autoimmune diseases. According to the report, the global gamma T cell therapy is expected to witness tremendous growth in the coming years and the market is expected to flourish with several potential candidates for the treatment of a wide variety of diseases.
Despite several limiting factors in the growth of the market, including low physical frequency, high development costs and strict regulatory guidelines, the overall market will follow a trajectory. This is mainly due to the increasing partnerships and collaborations between the pharmaceutical companies, increasing investment for conducting research and development activities.
Key players in the market are Acopedia, Takeda Pharma, TC Biopharma and Adapate Therapeutics, which have a robust clinical pipeline of candidate gamma-delta T cells.
In the coming years, the subsequent rise in cancer prevalence and the rate at which conventional therapies fail will create an unmet need for the development of new therapies that will drive the gamma-delta T-cell therapy market. In addition, the exploitation of the therapy in the treatment of other diseases will also stimulate the growth of marker.
In addition, it is analyzed that North America will maintain the top position in the global market due to the rising geriatric population and increasing government initiatives to promote new therapies. In the forecast period, Europe and Asia-Pacific will also emerge as a potential market due to the increase in awareness among the population of the region.
- Commercialization Market potential after market launch: > USD 4 billion 4
- Understanding Key Drugs in Research and Development
- Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight
- Gamma Delta T Cell Cancer Therapy In Clinical Trials: > 15 Therapies
- Gamma Delta T Cell Cancer Therapy Market Opportunity by Type of Cancer:
- Adopted Approaches for Gamma Delta T Cell Therapy
Main topics covered:
1. Introduction to Gamma Delta T Cell Therapy
1.1 Emerging role of T cell-based immunotherapies
1.2 Overview of Gamma Delta T Cell Therapy
2. Gamma Delta T Cell Therapy vs. Conventional Therapies
2.1 Gamma Delta T cell therapy vs. CAR T cell therapy
2.2 Gamma Delta T cell therapy vs. Tumor-infiltrating lymphocyte therapy
2.3 Gamma Delta T cell therapy vs. Immune Checkpoint Inhibitors
2.4 Gamma Delta T Cell Therapy vs. Monoclonal Antibodies
2.5 Gamma Delta T Cell Therapy vs. others
3. Role of Gamma Delta T Cells in Cancer
3.1 Gamma Delta T cells in cancer progression
3.2 Anti-tumor activity of gamma-delta T cells
4. Adopted Approaches for Gamma Delta T Cell Therapy
4.1 Gamma Delta T Cell as Bispecific Antibodies
4.2 CAR Gamma Delta T cells
5. Gamma Delta T Cell Therapy: Key Drugs in Research and Development
6. Global Gamma Delta T Cell Cancer Therapy Clinical Pipeline Overview
6.1 By country
6.2 By company
6.3 On indication
6.4 By phase
7. Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight
7.3 Phase I
7.4 Phase II/III
8. Gamma Delta T Cell Therapy in Leukemia
8.1 The role of gamma-delta T cells in leukemia
8.2 Ongoing clinical research in acute leukemia
8.3 Clinical studies in chronic lymphocytic leukemia
8.4 Future market opportunities of gamma-delta T cells in leukemia
9. Gamma Delta T Cell Therapy in Lung Cancer
9.2 Ongoing research and development
9.3 Future Market Opportunities of Gamma Delta T Cell Therapy in Lung Cancer
10. Gamma Delta T cells in breast cancer
10.2 Ongoing research and development in breast cancer
10.3 Future Market Opportunities of Gamma Delta T Cell Therapy in Breast Cancer
11. Gamma Delta T Cells in Colorectal Cancer
11.1 Function of Gamma Delta T cells in colorectal cancer
11.2 Ongoing clinical trials in colorectal cancer
11.3 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer
12. Gamma Delta T Cells in Pancreatic Cancer
12.2 Ongoing research and development in pancreatic cancer
12.3 Future market potential of Gamma Delta therapy in pancreatic cancer
13. Current Clinical Research on Other Cancers
13.1 Ongoing clinical studies in neuroblastoma
13.2 Ongoing clinical studies in glioblastoma
13.3 Ongoing research and development in head and neck cancer
14. Gamma Delta T Cell Therapy Market Overview
14.1 Current Market Scenario
14.2 Market Potential of the Gamma Delta T Cell Therapy Market
15. Market Dynamics of Gamma Delta T Cell Therapy
15.1 Gamma Delta T Cell Therapy Market: Favorable Parameters
15.2 Gamma Delta T Cell Therapy Market: Challenges
16. Gamma Delta T Cell Therapy Future Prospects
17. Competitive Landscape
17.2 Adjusting Therapeutics
17.4 Cytomed Therapies
17.6 GammaDelta Therapeutics
17.8 Kiromic Biopharmaceuticals
17.9 Lava therapies
17.10 Takeda Pharmaceuticals
17.11 TC Biopharm
For more information about this report, visit https://www.researchandmarkets.com/r/ze1yv6